Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Late introduction of cyclosporine or everolimus versus delayed cyclosporine with MMF after liver transplantation
2009-017192-26Phase 3Completed
- Sponsor
- Free State of Bavaria represented by Regensburg University represented by Regensburg University Hospital represented by
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ciclosporin, everolimus and mycophenolate mofetil in None (3 arms), sponsored by Free State of Bavaria represented by Regensburg University represented by Regensburg University Hospital represented by. Primary endpoint: Renal function at 12 months. Started Feb 2011; status: completed.
02
Drugs
ciclosporineverolimusmycophenolate mofetil
Beyond the preview
Go deeper on 2009-017192-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017192-26.